Split History
ETFs Holding MYGN »    MYGN Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Myriad Genetics is a precision medicine company acting as a trusted advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests include: myRisk™ Hereditary Cancer for assessing the risks for hereditary cancers; BRACAnalysis® for assessing the risk of developing breast and ovarian cancer; riskScore™ that improves Co.'s myRisk Hereditary Cancer test; GeneSight® to support psychotropic drug selection for depressed patients; Vectra®DA for assessing the disease activity of rheumatoid arthritis; and Prolaris® for assessing the aggressiveness of prostate cancer. Co. also provides pharmaceutical and clinical services. According to our MYGN split history records, Myriad Genetics has had 2 splits.
MYGN split history picture
Myriad Genetics (MYGN) has 2 splits in our MYGN split history database. The first split for MYGN took place on September 12, 2000. This was a 2 for 1 split, meaning for each share of MYGN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. MYGN's second split took place on March 26, 2009. This was a 2 for 1 split, meaning for each share of MYGN owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.

When a company such as Myriad Genetics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the MYGN split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Myriad Genetics shares, starting with a $10,000 purchase of MYGN, presented on a split-history-adjusted basis factoring in the complete MYGN split history. MYGN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/15/2009
End date: 12/13/2019
Start price/share: $24.75
End price/share: $25.58
Dividends collected/share: $0.00
Total return: 3.35%
Average Annual Total Return: 0.33%
Starting investment: $10,000.00
Ending investment: $10,334.94
Years: 10.00
Date Ratio
09/12/20002 for 1
03/26/20092 for 1
MYGN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MYL Split History
NAVB Split History
NBS Split History
NBY Split History
NEOG Split History
NNVC Split History
NRCIB Split History
NSPH Split History
NSPR Split History
NURO Split History

Also explore: MYGN shares outstanding history

Protalix BioTherapeutics, Inc. (PLX)
Euroseas Ltd. (ESEA)
QuickLogic Corporation (QUIK)
iMedia Brands, Inc. (IMBI)
Akers Biosciences, Inc. (AKER)
NeuroMetrix, Inc. (NURO)
TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MYGN Insider Buying

MYGN Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.